Zinc;butane;[(E)-hept-3-en-4-yl]-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]azanide
C17H34N2OZn — CID 10521635
Data last refreshed: (MolForge compound catalog, from PubChem)
About Zinc;butane;[(E)-hept-3-en-4-yl]-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]azanide
Zinc;butane;[(E)-hept-3-en-4-yl]-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]azanide (PubChem CID 10521635) has the molecular formula C17H34N2OZn and a molecular weight of 347.86 g/mol. Its IUPAC name is zinc;butane;[(E)-hept-3-en-4-yl]-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]azanide.
Molecular Properties
| Compound Name | Zinc;butane;[(E)-hept-3-en-4-yl]-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]azanide |
|---|---|
| PubChem CID | 10521635 |
| Molecular Formula | C17H34N2OZn |
| Molecular Weight | 347.86 g/mol |
| Exact Mass | 346.20 |
| IUPAC Name | zinc;butane;[(E)-hept-3-en-4-yl]-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]azanide |
| SMILES | CC/C=C(\CCC)[N-]N1CCC[C@H]1COC.[CH2-]CCC.[Zn+2] |
| InChI | InChI=1S/C13H25N2O.C4H9.Zn/c1-4-7-12(8-5-2)14-15-10-6-9-13(15)11-16-3;1-3-4-2;/h7,13H,4-6,8-11H2,1-3H3;1,3-4H2,2H3;/q2*-1;+2/b12-7+;;/t13-;;/m0../s1 |
| InChIKey | TYQAMNNEIMDLST-VDHJBGAKSA-N |
| XLogP | 5.10 |
| TPSA | 26.57 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 2 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 21 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 347.86 |
| LogP ≤ 5 | 5.10 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 2 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Carbo_cation/anion', 'substructure': 'N/A'}, {'alert_name': 'heavy_metal', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 10521635 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.